Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 1/Phase 2

First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia

David Wilson · with Rio pharmaceuticals Inc. · NCT05374278

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 40–75 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Phase 1, Phase 2
Target enrollment
102
US sites recruiting
1
Study start
November 2, 2021
Record last updated
April 17, 2025

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This is a first in human study that will assess the safety and diagnostic performance of [18F]RP-115 (fluorine-18 labeled RP115), a positron emission tomography (PET) agent. This agent has the potential to identify the early changes that occur in the brains of patients with Alzheimer's disease (AD) and frontotemporal dementia (FTD).

Being studied: [18F]RP-115 PET/MRI or PET/CT and MRI

Conditions: Alzheimer Disease; Frontotemporal Dementia; Dementia

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Age 40-75
  • Age-suitable BMI
  • Ability to provide written informed consent and willingly comply with protocol requirements or has a legal authorized representative/guardian who provides surrogate informed consent.
  • No apparent physical disorder.
  • Radial, ulnar, or brachial artery suitable for catheterization.
  • Non-smoker, and not taking OTC nicotine cessation - to limit peripheral metabolism events.
  • Devoid of CNS prescription drugs for three weeks - to limit peripheral metabolism events.

For Cohort 2B and 2C:

  • Must have a study partner (informant) who spends a minimum average of 5 hours per week with the participant (e.g. family member, significant other, friend, caregiver), is generally aware of the participant's daily activities, can provide information about the participant's cognitive and functional performance, and will accompany the participant in all study procedure.
  • Recent (within 6 mo.) MME clinical scores.

Exclusion Criteria

  • Unable to provide written informed consent and unwilling to comply with protocol requirements, or does not have a legal authorized representative/guardian who can provide surrogate informed consent.
  • Inadequate arterial access.
  • Receipt of radioisotope \< 5 half-lives within [18F]RP-115 imaging- as to not confound any scans with radiation background for previous scanning, and unsuitable organ dosimetry thresholds from previous (> two weeks) PET scans.
  • The performed [18F]RP-115 scan(s) must not represent > 3 PET studies total within one year.
  • Contra-indication to magnetic resonance, including permanent pacemaker, implantable metallic device, etc.; or severe claustrophobia.
  • Participants who are pregnant (female patients of childbearing age will be tested prior to injection of tracer- positive test excludes from the study)
  • Participants who are breast-feeding.
  • Have a medical condition or other circumstances that in the opinion of the project physicians would significantly decrease chances of obtaining reliable data, achieving the study objective or completing the study.

Recruiting US locations

  • China Basin, UCSF

    San Francisco, CA 94107

    Site contact: David Wilson, MD, PhD · david.m.wilson@ucsf.edu

Study contacts (from the official record)

  • David Wilson, MD, PhD · 415-514-6229 · david.m.wilson@ucsf.edu
  • Henry Vanbrocklin, PhD · 415-353-4569 · henry.vanbrocklin@ucsf.edu
All neurology studies in California →
First-in-Human Evaluation of an Astrocytic Glutamate Transporter… (NCT05374278) | Bored Studies